靶向PI3K-Akt-mTOR信号通路抑制剂的研究进展  

Advances in kinase inhibitors targeting PI3K-Akt-mTOR signal transduction pathway

作　　者：张超[1] 杨娜[1] 章雄文[1] 丁健[1] 

机构地区：[1]中国科学院上海药物研究所新药研究国家重点实验室肿瘤药理组,上海201203

出　　处：《中国癌症杂志》2006年第12期1064-1070,共7页China Oncology

基　　金：国家自然科学基金面上项目(No:30371645)

摘　　要：PI3K-Akt-mTOR信号通路控制着众多在肿瘤发生发展中至关重要的细胞生物学过程,包括细胞凋亡、转录、翻译、代谢、血管新生以及细胞周期的调控。遗传学上的改变和生化条件引起的激活经常发生在恶变早期和肿瘤进展期,同时,信号通路激活程度也是肿瘤患者预后的重要指标。因此抑制该信号通路成为肿瘤预防和肿瘤靶向治疗的热点。对于该信号通路的各个激酶,均有多种抑制剂处于临床前和临床研究阶段。PI3K-Akt-mTOR acts as an important controller in progress of tumorigenesis including apoptosis, transcription, translation, metabolism, angiogenesis and cell cycle. Genetic alterations and biochemical factors could occur in the early stage of neoplasm and tumor progress. To some degree, the activation of the signal transduction pathway could be served as a prognostic factor for tumor patients. Targeting PI3K-Akt-mTOR is becoming a hot area in tumor therapeutics. Many inhibitors against kinases involved in this signaling pathway are in preclinical and clinical trials. In our paper.

关 键 词：PI3K—Akt—mTOR 激酶抑制剂 肿瘤 

分 类 号：R73-361[医药卫生—肿瘤]